Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
about
Current and emerging treatment options for patients with relapsed myelomaVenous thromboembolism in cancer patients: an underestimated major health problemGuidance for the prevention and treatment of cancer-associated venous thromboembolismEnoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomideArterial thrombosis in four patients treated with thalidomideVenous thromboembolism and prognosis in cancer.Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based studyRecent developments in hematopoietic stem cell transplantation for multiple myeloma.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Treatment advances in multiple myeloma.Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosisPrimary prevention of venous thromboembolism in medical and surgical oncology patients.Epidemiology and pathophysiology of cancer-associated thrombosis.Cure of myeloma: hype or reality?A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Pharmacotherapy of multiple myeloma.Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.New therapies in multiple myeloma.Thromboembolic events with lenalidomide-based therapy for multiple myelomaMechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Cancer, clots and consensus: new understanding of an old problem.Cancer and thrombosis: implications of published guidelines for clinical practice.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.Anticoagulation for prevention and treatment of cancer-related venous thromboembolism.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Reversible pulmonary hypertension related to thalidomide treatment for multiple myeloma.Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer.Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha.Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)-alpha-stimulated cells.The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification.Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.
P2860
Q26830878-B6B1AB62-F440-4E1A-B98B-EC54601F81E0Q26852015-27DA1CC7-B81D-4943-8A01-A13AA7CA0ADDQ28069131-5E0C1688-FEDE-441E-963F-BE441FD6ED6CQ28199907-FD7752BF-A3EB-4857-B493-6A75EB2EE09BQ28212339-D5386BCD-DD9E-4EB4-8AC9-FAA138F8D716Q33886515-06B1F919-52E6-4C05-A522-7B628BD801A4Q33931754-CEE73D34-84DD-4AC7-837C-DB75889C727FQ35121623-68AFA79F-CB84-4BE3-A740-92208C8B5BF6Q35174604-1D9C1BA2-E184-417F-B02F-5028232089CEQ35688848-DB1D2064-CBFB-454A-8101-57C7ABFC050BQ35802182-66BF049F-064F-479D-B318-2DEF48392D7CQ35860785-02692B27-8505-49E0-B544-E33B00EC96FEQ35860789-26E4230F-CB1E-4827-933B-DDC039612011Q35949091-E2955836-C98B-4871-AA73-50FFBCAAC19DQ36381565-1A562E6B-3AA4-4401-8180-2AC3E7BF68E7Q36429735-BE9D8A3E-4573-46BC-9F55-FB6E0A867309Q36948554-F5B1B327-32B4-456F-B342-9EE17C6B0F67Q36986576-6623A3B7-D81D-4974-9F97-966A2F688659Q37038367-ADE20C0A-A564-48A1-B3AC-DF6D369858A1Q37038711-46E0A7DB-1694-4C48-9D18-BEA371B67CCAQ37393386-A13F3CB3-94B6-47B5-943A-CF1EB2152E3CQ37533816-4A295B30-0FD4-4E1A-80BF-C30107B75EA8Q37831402-8C1F31A5-B320-4198-BB88-A0C5C168840FQ37991783-B6E5940B-D9BC-4265-92D1-C71A599388E0Q38096441-2F0BEB9D-82A1-4D0E-931C-4595F9FBB60FQ38170453-9424931D-E52C-4A0D-A0DA-7C8DB519ECDCQ39256501-2D0EA52A-888C-4F77-A3FD-5C3A5E042D49Q39540696-22D72363-631E-44A3-A5A7-103622F7606FQ40373073-6900A181-CEEA-4893-9864-69C9D1EDC6FAQ41241927-1C6E8220-19AD-42B4-8277-47A290D41434Q44356203-2229D33D-C8F9-40CC-BF82-FBCB208532F2Q44386865-BD78A031-F745-403F-A74D-FCC5C379A5F4Q44537656-C732D35A-B9EE-485F-90AF-CF055C615644Q44693044-C96084C7-EA1B-4F05-BB6C-D6D847CBDF68Q44770291-0A19211A-59CB-4ABF-9374-6B221287A7A7Q44964053-579DA907-6A1E-4C5A-A855-C319094D7488Q45095148-F8F19679-44D3-4D9B-B390-795EFE6C90CBQ45252391-68912422-FF45-408D-B658-32E3279E0D63Q46543493-EC6FDD46-795F-442D-8E65-426A87D2AE59Q53584702-4E656266-31D3-4403-8FCE-E5334040BB2E
P2860
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Deep-vein thrombosis in patien ...... idomide-dexamethasone therapy.
@en
Deep-vein thrombosis in patien ...... idomide-dexamethasone therapy.
@nl
type
label
Deep-vein thrombosis in patien ...... idomide-dexamethasone therapy.
@en
Deep-vein thrombosis in patien ...... idomide-dexamethasone therapy.
@nl
prefLabel
Deep-vein thrombosis in patien ...... idomide-dexamethasone therapy.
@en
Deep-vein thrombosis in patien ...... idomide-dexamethasone therapy.
@nl
P2093
P921
P1433
P1476
Deep-vein thrombosis in patien ...... idomide-dexamethasone therapy.
@en
P2093
Claudia Cellini
Delia Cangini
Elena Zamagni
Gualtiero Palareti
Lelia Valdrè
Luciano Masini
Michele Cavo
Michele Cini
Patrizia Tosi
Sante Tura
P304
P356
10.1182/BLOOD-2002-06-1674
P407
P577
2002-09-01T00:00:00Z